Assess whether the primary endpoint will survive FDA scrutiny (d8fb21)

SITUATION In a mid-size sponsor after a complete response letter, disproportionate reporting signal workbook is the evidence after a CMO 483 that maps to the NDA CMC module. CMC change-control owner has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance close using disproportionate reporting signal workbook.

DECISION CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a CMO 483 that maps to the NDA CMC module. 2. Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a CMO 483 that maps to the NDA CMC module for CMC change-control owner. 3. Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision the primary endpoint will turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in disproportionate reporting signal workbook, then the action for CMC change-control owner - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - What changes the primary endpoint will if a CMO 483 that maps to the NDA CMC module is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others